The Next Frontier for 3-D Printing: Human Organs

Scientists are on their way to 3-D printing functioning large organs. In the meantime, the technology is being used to test drug responses in mini-systems.

A 3D printer constructs a model human figure in the exhibition '3D: printing the future' in the Science Museum on October 8, 2013 in London, England.
National Journal
Sophie Novack
See more stories about...
Sophie Novack
Dec. 27, 2013, midnight

Re­search­ers at Wake Forest Baptist Med­ic­al Cen­ter are em­bark­ing on a pro­ject that is so over­loaded with sci-fiesque ele­ments that if it were a movie, you might ques­tion the screen­writer’s cred­ib­il­ity.

The “body on a chip” pro­ject will use 3-D print­ing — or bioprint­ing — tech­no­logy to cre­ate mini hu­man-or­gan sys­tems about the size of a quarter to test the body’s re­sponse to drugs. It’s fun­ded by a $24 mil­lion grant from the De­fense De­part­ment to de­vel­op an­ti­dotes to very strong agents in the areas of chem­ic­al and bio­lo­gic­al war­fare.

The ul­ti­mate goal of bioprint­ing is to cre­ate large, func­tion­al, im­plant­able or­gans that will ad­dress the grow­ing gap between vi­able or­gan sup­ply and de­mand for trans­plants. Along the way, the sim­pler, mini-ver­sions can be used to more ef­fect­ively test drugs.

A few groups have been ex­per­i­ment­ing with bioprint­ing tis­sues and or­gans, but the body-on-a-chip pro­ject is unique in con­nect­ing the struc­tures to­geth­er. The chip will be able to test the im­pact of agents — in­clud­ing in­tense chem­ic­al weapons, more main­stream drugs, and treat­ments — on the hu­man body. The pro­ject of­fers an al­tern­at­ive to an­im­al test­ing — which is of­ten in­ef­fi­cient and in­ac­cur­ate for meas­ur­ing hu­man re­sponses — and en­ables the lab to test the full sys­tem’s re­sponse, rather than just one type of or­gan.

Sci­ent­ists star­ted mak­ing tis­sues by hand about 25 years ago. Us­ing a tech­nique known as scaf­fold­ing, cells from a pa­tient’s tis­sue were layered on 3-D molds and grown in an in­cub­at­or out­side the body. Us­ing bioprint­ing tech­no­logy, they are now able to feed the same in­form­a­tion in­to a com­puter to build the tis­sue.

Print­ing came about as a way to scale up the tis­sues and or­gans we were already cre­at­ing by hand,” says An­thony Atala, dir­ect­or of the Wake Forest In­sti­tute of Re­gen­er­at­ive Medi­cine in North Car­o­lina and the lead in­vest­ig­at­or on the pro­ject. Bioprint­ing en­ables re­search­ers to cre­ate tis­sues with much great­er pre­ci­sion and ac­cur­acy.

Atala ex­plains the four tis­sues types in or­der of com­plex­ity: Simplest are flat struc­tures like skin; second are tu­bu­lar struc­tures, such as blood ves­sels or wind­pipes; third are hol­low non-tu­bu­lar or­gans, such as the stom­ach, blad­der, and uter­us; and last and most com­plex by far are sol­id or­gans, such as the heart, kid­ney, and liv­er. These have more cells per area, more cell types, and high­er nu­tri­tion re­quire­ments, and they need much more vas­cu­lar­ity and blood sup­ply.

To this point, sci­ent­ists have only im­planted the first three types from hand­made tis­sues in pa­tients. No bioprin­ted struc­ture has been im­planted.

The mini-or­gans are small enough that they don’t re­quire a com­plex vas­cu­lar tree to sur­vive. The mini-liv­ers, hearts, lungs, and kid­neys are not fully func­tion­al nat­ive or­gans, but they mim­ic the func­tion­al­ity for the test­ing ap­plic­a­tion.

The Wake Forest lab has de­veloped one ma­chine to bioprint dif­fer­ent types of tis­sues. “It’s like with an inkjet print­er, where you have dif­fer­ent col­ors,” says Sang Jin Lee, a coin­vestig­at­or on the pro­ject. “Here we have dif­fer­ent nozzles and dif­fer­ent ma­ter­i­als and cells.”

The re­search­ers are bor­row­ing from com­puter mi­cro­chip and bi­o­sensing tech­no­logy. They will fo­cus on one or­gan type at a time, be­gin­ning with the liv­er. As each is de­veloped, it will be used to test drug re­sponses in­di­vidu­ally; once they are com­pleted, they will be con­nec­ted on the chip to test the full sys­tem re­sponse.

A small hand­ful of oth­er groups are de­vel­op­ing tech­no­lo­gies to print tis­sues, al­though gen­er­ally with a fo­cus on in­di­vidu­al or­gans, rather than the full sys­tem.

Or­gan­ovo, a start-up in San Diego, is us­ing bioprint­ing of tis­sues to im­prove re­search on drugs, with a re­cent fo­cus on the liv­er.

“Re­li­ance on an­im­al mod­els and cells in a petri dish [for test­ing] is prob­lem­at­ic, be­cause many dis­eases can’t get good an­im­al mod­els or don’t be­have sim­il­arly in petri dishes,” says Or­gan­ovo CEO Keith Murphy. The com­pany has suc­ceeded in bioprint­ing liv­er tis­sue that las­ted 40 days in a dish. Murphy says nor­mally the tis­sue stops func­tion­ing in two days, which is not help­ful for test­ing a drug that is ad­min­istered for two years.

Or­gan­ovo is fo­cused on the im­me­di­ate com­mer­cial im­pact of bioprint­ing, with test­ing done on each tis­sue in­de­pend­ently. “We’ve con­tem­plated put­ting [the parts] to­geth­er over time, but you don’t need 10 things to study the liv­er — you need the liv­er,” ex­plains Murphy.

“You can make liv­ing struc­tures act like liv­ing tis­sues,” he says. “You don’t need the full or­gan to have an im­pact.”

The Ad­vanced Man­u­fac­tur­ing Tech­no­logy Group at the Uni­versity of Iowa is bioprint­ing tis­sue with this idea in mind. Ibrahim Ozbolat, AMTech co­dir­ect­or and as­sist­ant pro­fess­or of mech­an­ic­al and in­dus­tri­al en­gin­eer­ing, is fo­cused on cre­at­ing tis­sue that would ac­com­pany — not ne­ces­sar­ily re­place — the pan­creas and pro­duce in­sulin to help pa­tients with dia­betes.

“We’re not in­ter­ested in mak­ing a full nat­ur­al pan­creas,” he says. “We’re work­ing on mak­ing something that is large enough and pro­duces enough in­sulin that is trans­plant­able.”

These pro­jects are all steps along the path to­ward bioprint­ing large or­gans, al­though that goal and its clin­ic­al ap­plic­a­tion is years in the fu­ture.

“[Bioprint­ing or­gans] is still sev­er­al bil­lion dol­lars away,” Murphy says. “If the fund­ing is provided in five years, it could hap­pen quickly. If it takes 20 years, it will be more over that time frame.”

The hope is that as the tech­no­lo­gies con­tin­ue to de­vel­op, the man­u­fac­tur­ing of or­gans could help solve the prob­lem of rap­idly grow­ing trans­plant wait-lists.

Atala notes that over two sets of 10 years, the num­ber of pa­tients on wait-lists has doubled, while the num­ber of or­gans trans­planted has in­creased by only 1 per­cent — a prob­lem the Amer­ic­an Hos­pit­al As­so­ci­ation has de­clared a pub­lic health crisis.

“This is really what drives us to do this,” he says. “Everything builds on the next step.”

What We're Following See More »
STAFF PICKS
What the Current Crop of Candidates Could Learn from JFK
14 hours ago
WHY WE CARE

Much has been made of David Brooks’s recent New York Times column, in which confesses to missing already the civility and humanity of Barack Obama, compared to who might take his place. In NewYorker.com, Jeffrey Frank reminds us how critical such attributes are to foreign policy. “It’s hard to imagine Kennedy so casually referring to the leader of Russia as a gangster or a thug. For that matter, it’s hard to imagine any president comparing the Russian leader to Hitler [as] Hillary Clinton did at a private fund-raiser. … Kennedy, who always worried that miscalculation could lead to war, paid close attention to the language of diplomacy.”

Source:
STAFF PICKS
Maher Weighs in on Bernie, Trump and Palin
15 hours ago
WHY WE CARE

“We haven’t seen a true leftist since FDR, so many millions are coming out of the woodwork to vote for Bernie Sanders; he is the Occupy movement now come to life in the political arena.” So says Bill Maher in his Hollywood Reporter cover story (more a stream-of-consciousness riff than an essay, actually). Conservative states may never vote for a socialist in the general election, but “this stuff has never been on the table, and these voters have never been activated.” Maher saves most of his bile for Donald Trump and Sarah Palin, writing that by nominating Palin as vice president “John McCain is the one who opened the Book of the Dead and let the monsters out.” And Trump is picking up where Palin left off.

Source:
×